RxDoctor Payments Data

Mukunda Singh, MD

Internal Medicine · Concord, NCNPI 1487185534

Payments from drug & device makers

$981in general payments, 2019–2025

Across 50 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$249
  • Novo Nordisk$182
  • Pfizer$138
  • Insulet Corporation$129
  • GSK$91
  • Boehringer Ingelheim$76
  • plus $116 from 4 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$981 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$50,742
Medicare patients
141
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$142,720
OzempicSemaglutide80$101,353
JardianceEmpagliflozin108$100,526
MounjaroTirzepatide81$94,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$73,292
TrulicityDulaglutide42$61,312
Tresiba Flextouch U-200Insulin Degludec31$39,537
XareltoRivaroxaban39$38,725
FarxigaDapagliflozin Propanediol13$20,554
Breo ElliptaFluticasone/Vilanterol33$20,140
LinzessLinaclotide23$15,779
Spiriva RespimatTiotropium Bromide14$7,085
Praluent PenAlirocumab13$6,744
SymbicortBudesonide/Formoterol Fumarate23$5,339
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$249$155,411123 claims
PfizerEliquis$138$142,720170 claims
Boehringer IngelheimJardiance, Spiriva Respimat$76$107,611122 claims
Novo NordiskOzempic$182$101,35380 claims
GSKTrelegy Ellipta, Breo Ellipta$91$93,432107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →